JP2009526010A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009526010A5 JP2009526010A5 JP2008553739A JP2008553739A JP2009526010A5 JP 2009526010 A5 JP2009526010 A5 JP 2009526010A5 JP 2008553739 A JP2008553739 A JP 2008553739A JP 2008553739 A JP2008553739 A JP 2008553739A JP 2009526010 A5 JP2009526010 A5 JP 2009526010A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- monoclonal antibody
- antibody
- hgfr
- cdr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06101345.4 | 2006-02-06 | ||
| EP06101345 | 2006-02-06 | ||
| PCT/EP2007/051066 WO2007090807A1 (en) | 2006-02-06 | 2007-02-05 | Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009526010A JP2009526010A (ja) | 2009-07-16 |
| JP2009526010A5 true JP2009526010A5 (enExample) | 2010-02-25 |
| JP5306828B2 JP5306828B2 (ja) | 2013-10-02 |
Family
ID=36616994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008553739A Active JP5306828B2 (ja) | 2006-02-06 | 2007-02-05 | 腫瘍の治療のための、抗ｍｅｔモノクローナル抗体、フラグメント及びそのベクター、並びに対応する製品 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US8388958B2 (enExample) |
| EP (2) | EP1981981B1 (enExample) |
| JP (1) | JP5306828B2 (enExample) |
| KR (1) | KR101429297B1 (enExample) |
| CN (1) | CN101379192B (enExample) |
| AT (1) | ATE514715T1 (enExample) |
| AU (1) | AU2007213804B2 (enExample) |
| BR (1) | BRPI0707480A8 (enExample) |
| CA (1) | CA2638889C (enExample) |
| CY (1) | CY1111884T1 (enExample) |
| DK (1) | DK1981981T3 (enExample) |
| EA (1) | EA015580B1 (enExample) |
| ES (1) | ES2368864T3 (enExample) |
| IL (1) | IL192879A (enExample) |
| MX (1) | MX2008009833A (enExample) |
| PL (1) | PL1981981T3 (enExample) |
| PT (1) | PT1981981E (enExample) |
| SG (2) | SG169382A1 (enExample) |
| SI (1) | SI1981981T1 (enExample) |
| WO (1) | WO2007090807A1 (enExample) |
| ZA (1) | ZA200806559B (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2014681A1 (en) | 2007-07-12 | 2009-01-14 | Pierre Fabre Medicament | Novel antibodies inhibiting c-met dimerization, and uses thereof |
| IL198545A0 (en) | 2008-05-14 | 2011-07-31 | Metheresis Translational Res Sa | High affinity binding site of hgfr and methods for identification of antagonists thereof |
| EP2127683A1 (en) * | 2008-05-29 | 2009-12-02 | Metheresis Translational Research SA | Anti-Met monoclonal antibody, fragments and derivatives thereof for use in tumor imaging, corresponding compositions and kits |
| PA8849001A1 (es) | 2008-11-21 | 2010-06-28 | Lilly Co Eli | Anticuerpos de c-met |
| EP2287197A1 (en) * | 2009-08-21 | 2011-02-23 | Pierre Fabre Medicament | Anti-cMET antibody and its use for the detection and the diagnosis of cancer |
| KR101671378B1 (ko) | 2009-10-30 | 2016-11-01 | 삼성전자 주식회사 | ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그의 용도 |
| KR101748707B1 (ko) * | 2009-11-27 | 2017-06-20 | 삼성전자주식회사 | ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그를 이용한 암 진단용 키트 |
| ES2993335T3 (en) | 2010-03-10 | 2024-12-27 | Genmab As | Monoclonal antibodies against c-met |
| WO2011125458A1 (ja) * | 2010-04-02 | 2011-10-13 | 富士レビオ株式会社 | 抗癌剤の効果の診断用マーカー |
| JP2013534515A (ja) * | 2010-06-01 | 2013-09-05 | モナシュ ユニバーシティ | プロセシングされていない受容体型チロシンキナーゼｃ−ＭＥＴに対する抗体 |
| RU2013114783A (ru) * | 2010-09-03 | 2014-10-10 | Академиа Синика | Anti-с-мет антитела и способы их применения |
| BR122014027420A2 (pt) | 2010-11-03 | 2019-08-20 | Argenx Bvba | Anticorpos anti c-met |
| EP2500036B1 (en) * | 2011-03-18 | 2014-05-07 | Metheresis Translational Research SA | MET inhibitors for enhancing radiotherapy efficacy |
| WO2013043452A1 (en) | 2011-09-20 | 2013-03-28 | Eli Lilly And Company | Anti-c-met antibodies |
| US9926364B2 (en) | 2011-11-03 | 2018-03-27 | Argen-X N.V. | Chimeric human-llama antigens and methods of use |
| TW201326193A (zh) | 2011-11-21 | 2013-07-01 | Genentech Inc | 抗－ｃ－ｍｅｔ抗體之純化 |
| WO2013079973A1 (en) | 2011-12-02 | 2013-06-06 | Di Cara Danielle Marie | Antibodies against hgf - receptor and uses |
| US8900582B2 (en) | 2011-12-22 | 2014-12-02 | Samsung Electronics Co., Ltd. | Deimmunized anti c-Met humanized antibodies and uses thereof |
| CN103382223B (zh) * | 2012-04-01 | 2015-06-10 | 上海益杰生物技术有限公司 | 针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽 |
| EP2863946A4 (en) * | 2012-06-21 | 2016-04-13 | Sorrento Therapeutics Inc | ANTIGEN-BINDING PROTEINS THAT BIND TO C-MET |
| ITTO20130012A1 (it) | 2013-01-09 | 2014-07-10 | Metheresis Translational Res S A | Nuovi frammenti anticorpali, relative composizioni ed usi |
| CN107001471B (zh) | 2014-09-16 | 2022-01-18 | 西福根有限公司 | 抗met抗体和组合物 |
| WO2016149116A1 (en) * | 2015-03-13 | 2016-09-22 | University Of Maryland, Baltimore | Antibodies targeting s100b and methods of use |
| CN107613974B (zh) | 2015-03-16 | 2021-01-15 | 塞尔德克斯医疗公司 | 抗-met抗体及其使用方法 |
| IT201800000534A1 (it) * | 2018-01-03 | 2019-07-03 | Procedimenti per la promozione della crescita cellulare degli isolotti pancreatici. | |
| GB201611123D0 (en) * | 2016-06-27 | 2016-08-10 | Euremab Srl | Anti met antibodiesand uses thereof |
| KR102443619B1 (ko) * | 2016-09-29 | 2022-09-14 | 미쓰비시 타나베 파마 코퍼레이션 | cMET 단일클론 결합제, 이의 약물 접합체 및 이의 용도 |
| TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法 |
| CN106872695B (zh) * | 2017-01-20 | 2019-06-11 | 中山大学 | 一种h7亚型禽流感病毒血凝素抗体间接elisa检测试剂盒 |
| IT201800000535A1 (it) * | 2018-01-03 | 2019-07-03 | Procedimenti per la cura del cancro. | |
| IT201800003875A1 (it) * | 2018-03-22 | 2019-09-22 | Metis Prec Medicine Sb S R L | Nuova combinazione di agenti terapeutici per il trattamento di un tumore e/o metastasi |
| MX2020010110A (es) | 2018-03-28 | 2020-11-06 | Mitsubishi Tanabe Pharma Corp | Conjugados de farmacos de agentes de union monoclonales de cmet, y usos de los mismos. |
| IT201800009282A1 (it) | 2018-10-09 | 2020-04-09 | Metis Prec Medicine Sb Srl | Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi |
| CN114340684B (zh) | 2019-09-16 | 2025-09-12 | 瑞泽恩制药公司 | 用于免疫pet成像的放射性标记的met结合蛋白 |
| AU2024282613A1 (en) | 2023-06-01 | 2025-11-20 | Pierre Fabre Medicament | Silenced antibody-based anti-met constructs for the treatment of tumors and metastasis |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) * | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US6814962B1 (en) | 1994-06-02 | 2004-11-09 | Aventis Pharma S.A. | Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same |
| US6214344B1 (en) | 1995-06-02 | 2001-04-10 | Genetech, Inc. | Hepatocyte growth factor receptor antagonists and uses thereof |
| HN2004000285A (es) | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
-
2007
- 2007-02-05 AU AU2007213804A patent/AU2007213804B2/en active Active
- 2007-02-05 PL PL07704350T patent/PL1981981T3/pl unknown
- 2007-02-05 ES ES07704350T patent/ES2368864T3/es active Active
- 2007-02-05 PT PT07704350T patent/PT1981981E/pt unknown
- 2007-02-05 JP JP2008553739A patent/JP5306828B2/ja active Active
- 2007-02-05 KR KR1020087016543A patent/KR101429297B1/ko active Active
- 2007-02-05 US US12/223,623 patent/US8388958B2/en active Active
- 2007-02-05 EA EA200870234A patent/EA015580B1/ru not_active IP Right Cessation
- 2007-02-05 AT AT07704350T patent/ATE514715T1/de active
- 2007-02-05 EP EP07704350A patent/EP1981981B1/en active Active
- 2007-02-05 CN CN2007800047097A patent/CN101379192B/zh active Active
- 2007-02-05 DK DK07704350.3T patent/DK1981981T3/da active
- 2007-02-05 CA CA2638889A patent/CA2638889C/en active Active
- 2007-02-05 EP EP10151809A patent/EP2192188A1/en not_active Withdrawn
- 2007-02-05 WO PCT/EP2007/051066 patent/WO2007090807A1/en not_active Ceased
- 2007-02-05 MX MX2008009833A patent/MX2008009833A/es active IP Right Grant
- 2007-02-05 SG SG201100805-9A patent/SG169382A1/en unknown
- 2007-02-05 BR BRPI0707480A patent/BRPI0707480A8/pt not_active Application Discontinuation
- 2007-02-05 SG SG201100806-7A patent/SG169383A1/en unknown
- 2007-02-05 SI SI200730720T patent/SI1981981T1/sl unknown
-
2008
- 2008-07-17 IL IL192879A patent/IL192879A/en active IP Right Grant
- 2008-07-28 ZA ZA2008/06559A patent/ZA200806559B/en unknown
-
2011
- 2011-09-26 CY CY20111100926T patent/CY1111884T1/el unknown
- 2011-11-04 US US13/373,101 patent/US8729043B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009526010A5 (enExample) | ||
| KR102470294B1 (ko) | 암을 치료하기 위한 항-pd1 항체 및 방사선의 조합 | |
| Jeong et al. | Novel anti-4-1BB× PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade | |
| CN116077647B (zh) | 喹啉衍生物与抗体的药物组合 | |
| US20200392239A1 (en) | Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer | |
| JP2010531140A5 (enExample) | ||
| TW202045539A (zh) | 抗ｃｅａｃａｍ５免疫偶聯物用於治療肺癌的用途 | |
| AU2021271647A1 (en) | Use of a multimeric anti-DR5 binding molecule in combination with a cancer therapy for treating cancer | |
| JP2020507339A (ja) | 抗ｇ−ｃｓｆ抗体及びその使用 | |
| JP2018536682A (ja) | Ｅｇｆｒ及び／またはｅｒｂｂ３遮断に耐性のある腫瘍の成長を低減または防止するための方法 | |
| US20250388682A1 (en) | Degradation of egfr using a bispecific binding agent | |
| JP7422070B2 (ja) | 癌の治療のための配合剤 | |
| CN105828841A (zh) | 抗-efna4抗体-药物缀合物 | |
| WO2025067400A1 (en) | Combination of anti-claudin 18.2/anti-4-1bb antibodies and second therapeutic agent in treatment of cancer | |
| WO2024148339A1 (en) | Use of a multimeric anti-dr5 antibody for treating cancer | |
| CN110152014B (zh) | 抗trailr2抗体-毒素-偶联物及其在抗肿瘤治疗中的药物用途 | |
| TW202430209A (zh) | 單獨使用雙特異性EGFR x CD28抗體或其與抗PD-1抗體組合使用治療癌症之方法 | |
| CN106963950B (zh) | 用于治疗肿瘤的联合用药物 | |
| AU2024298986C1 (en) | Pharmaceutical composition containing anti-nectin4 antibody-drug conjugate and anti-pd-1 antibody and use thereof | |
| US20260022189A1 (en) | DEGRADATION OF cMET USING A BISPECIFIC BINDING AGENT | |
| Burke | Targeting T-cells to Acute Myeloid Leukemia with a Novel Bispecific Antibody Format | |
| KR20230061499A (ko) | Pd-1 저해제 투여에 의한 암 통증 치료 방법 | |
| KR20250029133A (ko) | 암 치료를 위한 표피성장인자 수용체 티로신 키나제 억제제를 포함하는 조합물 | |
| Stringer et al. | American Society of Hematology 60th Annual Meeting and Exposition. San Diego, California, USA-December 1-4, 2018 | |
| Stringer et al. | American Society of Hematology 60th Annual Meeting and Exposition |